Cargando…

Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China

The use of aspirin for primary prevention of cardiovascular disease (CVD) in patients with diabetes mellitus (DM) is associated with lower rates of cardiovascular events but increased risks of bleeding complications. We aimed to examine the cost-effectiveness of aspirin therapy for primary preventio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Minghuan, Li, Pengchao, You, Joyce Hoi-sze, Zheng, Xinglong, Deng, Jizhao, Zhao, Mingyue, Feng, Liuxin, Fang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886850/ https://www.ncbi.nlm.nih.gov/pubmed/31790409 http://dx.doi.org/10.1371/journal.pone.0224580

Ejemplares similares

Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events
por: Djatche, Laurence M., et al.
Publicado: (2018)

Aspirin for primary prevention of cardiovascular disease
por: Nansseu, Jobert Richie N., et al.
Publicado: (2015)

Aspirin for Primary Prevention of Cardiovascular Disease
por: Kim, Ji Hye, et al.
Publicado: (2019)

Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events
por: Sylvester, Katelyn W, et al.
Publicado: (2013)

Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018
por: Christensen, Mikkel B., et al.
Publicado: (2021)

Aspirin overutilization for the primary prevention of cardiovascular disease
por: VanWormer, Jeffrey J, et al.
Publicado: (2014)

Aspirin for primary prevention of cardiovascular disease in diabetes
por: Xing, Ying, et al.
Publicado: (2019)

Aspirin for the primary prevention of cardiovascular disease in the elderly
por: O’Sullivan, Jack W
Publicado: (2019)

Use and Misuse of Aspirin in Primary Cardiovascular Prevention
por: Coccheri, Sergio
Publicado: (2017)

Aspirin in primary prevention of cardiovascular disease in diabetes
por: Papazafiropoulou, Athanasia K., et al.
Publicado: (2021)

Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
por: Petersohn, Svenja, et al.
Publicado: (2020)

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
Publicado: (2010)

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
por: De Berardis, Giorgia, et al.
Publicado: (2009)

Cost‐Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease
por: Michaud, Tzeyu L., et al.
Publicado: (2015)

Use of Aspirin and Statin as primary prevention for cardiovascular diseases
por: Alkhail, Bahaa Aba, et al.
Publicado: (2016)

Aspirin for Primary Prevention of Cardiovascular Diseases: “WALTZ” with the Evidence
por: Dimitriadis, Kyriakos, et al.
Publicado: (2022)

Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis
por: Zhao, Binghao, et al.
Publicado: (2021)

Aspirin as Primary Prevention of Acute Coronary Heart Disease Events
por: Glasser, Stephen P., et al.
Publicado: (2014)

Aspirin for Prevention of Cardiovascular Disease
por: Mendy, Vincent L., et al.
Publicado: (2017)

Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease
por: Chen, Yinong, et al.
Publicado: (2021)

Aspirin for the Primary Prevention of Cardiovascular Events: A systematic review and meta-analysis comparing patients with and without diabetes
por: Calvin, Andrew D., et al.
Publicado: (2009)

Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran
por: Amirsadri, Mohammadreza, et al.
Publicado: (2017)

Impact of video-led educational intervention on uptake of influenza vaccine among the elderly in western China: a community-based randomized controlled trial
por: Jiang, Minghuan, et al.
Publicado: (2022)

Which people should take aspirin for primary prevention of cardiovascular disease?
por: Lozano, Roberto, et al.
Publicado: (2015)

Should Aspirin Be Used for the Primary Prevention of Cardiovascular Disease in the General Population?
por: Huang, Qing-Yu, et al.
Publicado: (2015)

Aspirin Use for Primary Cardiovascular Prevention During the COVID-19 Pandemic
por: Siegel, Arthur J.
Publicado: (2021)

Aspirin for Primary Prevention of Cardiovascular Events: Meta-Analysis of Randomized Controlled Trials and Subgroup Analysis by Sex and Diabetes Status
por: Xie, Manling, et al.
Publicado: (2014)

Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis
por: Ma, Hua, et al.
Publicado: (2021)

Budget Impact of Appropriate Low-Dose Aspirin Use for Primary and Secondary Cardiovascular Event Prevention in the Managed Care Setting
por: Carlton, Rashad, et al.
Publicado: (2018)

Pros and Cons of Aspirin Prophylaxis for Prevention of Cardiovascular Events in Kidney Transplantation and Review of Evidence
por: Khalil, Muhammad Abdul Mabood, et al.
Publicado: (2019)

Aspirin for primary prevention in the elderly
por: Saad, Marwan, et al.
Publicado: (2019)

Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins
por: De Berardis, Giorgia, et al.
Publicado: (2007)

Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis
por: Stegeman, Inge, et al.
Publicado: (2015)

The Efficacy And Safety Of Aspirin As The Primary Prevention Of Cardiovascular Disease: An Updated Meta-Analysis
por: Xie, Wenchao, et al.
Publicado: (2019)

Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach
por: Cofer, Lucas B., et al.
Publicado: (2022)

Low-dose Aspirin for Primary Prevention of Cardiovascular Events in Postmenopausal Women with Type-2 Diabetes: The Prescriptive Approach in the Real World
por: Maiello, Maria, et al.
Publicado: (2021)

Aspirin in the Modern Era of Cardiovascular Disease Prevention
por: Murphy, Ella, et al.
Publicado: (2021)

Access to anticancer medicines in public hospitals of Northwestern China
por: Ma, Yue, et al.
Publicado: (2023)

Aspirin in primary prevention: who is the target?
por: Gatto, Laura, et al.
Publicado: (2019)

Aspirin for primary prevention: Is this the end of the road?
por: Singal, Aayush Kumar, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8jsfgusaseruqcsb75t72ptkf8